Dr. Elana Fertig’s research develops computational methods for a systems biology approach to model the response and resistance to cancer therapies for applications in precision medicine.
She is collaborating with NFCR-supported scientist, Dr. Lisa Coussens. Their research is identifying and validating signatures of different cell states to predict a patient’s response to four different therapies administered sequentially to treat triple negative breast cancer (TNBC), the most difficult-to-treat breast cancer.
Dr. Fertig’s expertise in single-cell multi-omics algorithm development and their application to analysis of molecular/cellular pathways of therapeutic response/resistance in cancer will facilitate the uncovering of the molecular and cellular mechanisms underlying response and resistance to immunotherapy.
Impact
This collaborative research will help stratify patients and guide precision delivery of immunotherapy and monitor patient’s response and resistance to therapy. Importantly, these approaches will be applicable across cancer types beyond TNBC.





